Hong Kong-listed Metis TechBio said on Monday it has entered ​into a collaboration agreement with Eli ‌Lilly worth up to $1.1 billion to research and develop tissue-specific drug delivery technologies.

Log in or sign up to comment.

No comments yet.

← Back to stories

Create FREE account

or login to continue

Signup with GoogleSignup with GitHubSignup with BlueskySignup with Blacksky
Sign up with email

Already have an account? Log in